» Articles » PMID: 33996737

Structure Activity Relationship of -Substituted Phenyldihydropyrazolones Against Amastigotes

Overview
Journal Front Chem
Specialty Chemistry
Date 2021 May 17
PMID 33996737
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Current drugs for Chagas disease have long treatment regimens with occurrence of adverse drug effects leading to poor treatment compliance. Novel and efficacious medications are therefore highly needed. We previously reported on the discovery of NPD-0227 (2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one) as a potent inhibitor of (pIC = 6.4) with 100-fold selectivity over human MRC-5 cells. The present work describes a SAR study on the exploration of substituents on the phenylpyrazolone nitrogen. Modifications were either done directly onto this pyrazolone nitrogen or alternatively by introducing a piperidine linker. Attention was pointed toward the selection of substituents with a cLogP preferably below NPD-0227s cLogP of 3.5. Generally the more apolar compounds showed better activities then molecules with cLogPs <2.0. Several new compounds were identified with potencies that are in the same range as NPD-0227 (pIC = 6.4) and promising selectivities. While the potency could not be improved, valuable SAR was obtained. Furthermore the introduction of a piperidine linker offers new opportunities for derivatization as valuable novel starting points for future drug discovery.

Citing Articles

New Amino Naphthoquinone Derivatives as Anti- Agents Targeting Trypanothione Reductase.

Espinosa-Bustos C, Ortiz Perez M, Gonzalez-Gonzalez A, Zarate A, Rivera G, Belmont-Diaz J Pharmaceutics. 2022; 14(6).

PMID: 35745694 PMC: 9228152. DOI: 10.3390/pharmaceutics14061121.

References
1.
Bennion B, Be N, McNerney M, Lao V, Carlson E, Valdez C . Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B. 2017; 121(20):5228-5237. DOI: 10.1021/acs.jpcb.7b02914. View

2.
Prata A . Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2002; 1(2):92-100. DOI: 10.1016/S1473-3099(01)00065-2. View

3.
Urbina J, Gascon J, Ribeiro I . Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2016; 374(2):189. DOI: 10.1056/NEJMc1514453. View

4.
Pinazo M, Guerrero L, Posada E, Rodriguez E, Soy D, Gascon J . Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother. 2012; 57(1):390-5. PMC: 3535922. DOI: 10.1128/AAC.01401-12. View

5.
Meirelles M, Miranda C, De Souza W, Barbosa H . Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur J Cell Biol. 1986; 41(2):198-206. View